A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Itacitinib

DRUG

Itacitinib Placebo

Trial Locations (18)

Palm Desert

Pasadena

Lake Mary

Ocala

Palm Harbor

Tampa

Tavares

Lexington

Worcester

Lansing

Raleigh

Middleburg Heights

Duncansville

Florence

Austin

Katy

Spokane

Carolina